About JSAAE
From president
How to join us
Annual meeting
Information
WC6 New
announcement
AATEX Journal
Link
Other's


6th World Congress on Alternatives & Animal Use in the Life Sciences
-Review progress made toward the 3Rs-



Vol.14, Special Issue
March 31, 2008

Proceedings
Page 1-177
 Page 179-327
 Page 329-507
 Page 509-668
 Page 669-809



Page 329-507

  1. Multimedia software for demonstrating animal experiments in pharmacology
    C. R. Patil, 329-332.
  2. U.S. perspective on the "consideration of alternatives" regulatory requirement
    J. Kulpa-Eddy and K. Adams, 333-336.
  3. Update on the Colipa research programme for development of in vitro alternative methods for eye irritation
    P. McNamee, L. Declercq, A. De Smedt, B. De Wever, C. Faller, J. Harbell, P. Jones, M. Marrec-Fairley, W. Pape, U. Pfannenbecker, K. Schroeder, M. Tailhardat, C. Van den Berghe and F. Van Goethem, 337-341.
  4. The use of the reconstructed Human Corneal Model (HCE) to assess in vitro eye irritancy of chemicals
    J. Cotovio, M.-H. Grandidier, D. Lelièvre, C. Bremond, N. Flamand, S. Loisel-Joubert, A. Van Der Lee, C. Capallere, J.-R. Meunier and J. Leclaire, 343-350.
  5. In vitro acute skin irritancy of chemicals using the validated EPISKIN model in a tiered strategy -Results and performances with 184 cosmetic ingredients
    J. Cotovio, M.-H. Grandidier, D. Lelièvre, R. Roguet, E. Tinois-Tessonneaud and J. Leclaire, 351-358.
  6. Comparison of human skin irritaiton and photo-irritation patch test data with cellular in vitro assays and animal in vivo data
    D. Jirova, M. Liebsch, D. Basketter, E. Spiller, K. Kejlova, H. Bendova, M. Marriott and H. Kandarova, 359-365.
  7. BALB/c 3T3 cell transformation assays for the assessment of chemical carcinogenicity
    A. Sakai, 367-373.
  8. The COLIPA strategy for the development of in vitro alternatives: Skin sensitisation
    P. Aeby, T. Ashikaga, W. Diembeck, D. Eschrich, F. Gerberick, I. Kimber, M. Marrec-Fairley, G. Maxwell, J.-M. Ovigne, H. Sakaguchi, M. Tailhardat and S. Teissier, 375-379.
  9. Application of a systems biology approach for skin allergy risk assessment
    G. Maxwell and C. MacKay, 381-388.
  10. The EPISKIN Phototoxicity Assay (EPA): Development of an in vitro tiered strategy to predict phototoxic potential
    D. Lelièvre, P. Justine, F. Christiaens, N. Bonaventure, J. Coutet, L. Marrot, E. Tinois-Tessonneaud and J. Cotovio, 389-396.
  11. In vitro cytotoxicity asssessment of selected nanoparticles using human skin fibroblasts
    F. Dechsakulthorn, A. Hayes, S. Bakand, L. Joeng and C. Winder, 397-400.
  12. Genotoxicity assays with Episkin®, a reconstructed skin model: Towards new tools for in vitro risk assessment of dermally applied compounds?
    G. Ouëdraogo, M. Feltes, L. Bourouf, N. Flamand, E. Tinois-Tessoneaud and J.-R. Meunier, 401-405.
  13. Percutaneous absorption test -A case of effectiveness evaluation of skin-whitening cosmetics
    T. Koike, N. Nakashima, C. Urata, M. Arashima, H. Okumura and A. Takada, 407-410.
  14. Monocyte derived dendritic cells as a tool to predict skin sensitization: Limitations and opportunities
    D. Eschrich, U. Engels, J. Scheel and K. Schroeder, 411-413.
  15. Study on the prediction of human lip irritation from cosmetics materials using HeLa-MTT assay
    M. Morinaga, K. Shingaki, T. Mori and K. Yanagihara, 415-416.
  16. Assessment of the in vitro skin irritation of chemicals using the Vitrolife-SkinTM human skin model
    N. Morikawa, T. Kitagawa and K. Tomihata, 417-423.
  17. Validation of alternative endpoints for the LLNA: General considerations
    S. Casati, 425-427.
  18. Validation studies on an alternative endpoint for the local lymph node assay (LLNA-DA): Importance of the study management
    T. Omori, Y. Ikarashi, Y. Kanazawa, K. Idehara, H. Kojima, T. Sozu, K. Arima, H. Goto, T. Hanada, T. Inoda, T. Kosaka, E. Maki, T. Morimoto, S. Shinoda, N. Shinoda, M. Takeyoshi, M. Tanaka, M. Uratani, M. Usami, A. Yamanaka, T. Yoneda, I. Yoshimura and A. Yuasa, 429-432.
  19. Alternative application route in the LLNA provides crucial environmental enrichment and broadens the usability of vehicles
    U. Festersen, C. Rasmussen, T. M. R. Kjaer, N. K. Soni, E. L. Roggen and N. W. Berg, 433-436.
  20. In vitro hepatotoxicity testing in the early phase of drug discovery
    I. Horii and H. Yamada, 437-441.
  21. Genetic polymorphism in drug metabolism and toxicity: Linking animal research and risk assessment in man
    T. Satoh, 443-445.
  22. Renal drug transporters and nephrotoxicity
    N. Anzai and H. Endou, 447-452.
  23. Cisplatin-induced renal injury in LLC-PK1 cells
    Y. Kawai and M. Gemba, 453-456.
  24. Predictive in vitro cardiotoxicity and hepatotoxicity screening system using neonatal rat rat heart cells and rat hepatocytes
    T. Inoue, K. Tanaka, M. Mishima and K. Watanabe, 457-462.
  25. Toxicological and clinical computatuonal analysis by the Informatics and Computational Safety Analysis Staff of the US FDA/CDER
    D. R. Benz, E. J. Matthews, N. L. Kruhlak, A. A. Frid, B. L. Minnier and J. F. Contrera, 463-467.
  26. Evaluation of (Q)SAR models for the prediction of mutagenicity potential
    S. Ringeissen, R. Note, C. Dochez, N. Flamand, G. Ouedraogo-Arras and J.-R. Meunier, 469-473.
  27. Internationally harmonized processes for test method evaluation, validation and regulatory acceptance: The role of OECD guidance document 34
    L. M. Schechtman, 475-482.
  28. JaCVAM: An organization supporting the validation and peer review of new alternatives to animal testing
    H. Kojima, 483-485.
  29. A new signaling pathway of dioxin receptor ligands through targeted protein degradation
    S. Kato, Y. Fujii-Kuriyama and F. Ohtake, 487-494.
  30. A strategy to explore the target receptor of endocrine disruptors: Estrogen-related receptor r (ERR r) as a genuine acceptor of Bisphenol A
    A. Matsushima and Y. Shimohigashi, 495-497.
  31. What is better experimental design for in vitro comet assay to detect chemical genotoxicity?
    Y. F. Sakai, T. Nakamura and S. Kawaguchi, 499-504.
  32. Comparative evaluation of cosmetic formulations with different alternative methods for eye irritation
    A. Heppenheimer, A. Poth, R. Fautz and A. Fuchs, 505-507.



    Japanese English HOME CONTACT US Japanese Society for Alternatives to Animal Experiments